发明名称 |
VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINE |
摘要 |
The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher. |
申请公布号 |
US2017112922(A1) |
申请公布日期 |
2017.04.27 |
申请号 |
US201615251758 |
申请日期 |
2016.08.30 |
申请人 |
The University of Western Ontario |
发明人 |
KANG Chil-Yong;KIM Gyoung Nyoun |
分类号 |
A61K39/39;A61K39/29;C12N7/00;A61K39/21 |
主分类号 |
A61K39/39 |
代理机构 |
|
代理人 |
|
主权项 |
1. A prime boost combination vaccine, wherein the prime boost combination vaccine comprises: (a) an effective amount of a vaccine comprising an attenuated recombinant vesicular stomatitis virus (rVSV) of one serotype having a first modified M protein comprising the amino acid sequence of SEQ ID NO:4; and (b) an effective amount of a vaccine comprising a rVSV of another serotype having a second modified M protein comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. |
地址 |
London CA |